ReviewInnere Medizin (Heidelberg, Germany)2025
[Treatment of metastatic non-small cell lung cancer].
Review in Innere Medizin (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is among the most common and lethal malignancies worldwide, representing a particular oncological challenge due to its frequent diagnosis at an advanced, metastatic stage. Histopathologically, NSCLC is broadly classified into adenocarcinomas and squamous cell carcinomas. This distinction-along with programmed cell death-ligand 1 (PD-L1) expression and molecular pathology-guides therapeutic decision-making. At advanced stages, treatment options include not only traditional platinum-based chemotherapy but also immunotherapy with checkpoint inhibitors. Over the past decade, the rapid identification of actionable driver mutations has firmly established targeted therapies with tyrosine kinase inhibitors as a cornerstone of treatment, significantly improving the historically poor overall survival.
Indexed as
Identifiers
41105229What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.